v3.20.1
Collaboration with Janssen Biotech, Inc. (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Collaborative and license agreements      
Accounts receivable, net $ 6,362   $ 5,428
Accounts payable and accrued liabilities $ 12,709   11,832
Collaborative arrangement      
Collaborative and license agreements      
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 70 $ 72  
Collaborative arrangement | International      
Collaborative and license agreements      
International - AbbVie's share of profits (included in net revenues) 266 193  
Janssen Biotech Inc | Collaborative arrangement      
Collaborative and license agreements      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Accounts receivable, net $ 298   235
Accounts payable and accrued liabilities 445   $ 455
Janssen Biotech Inc | Collaborative arrangement | United States      
Collaborative and license agreements      
United States - Janssen's share of profits (included in cost of products sold) $ 450 $ 386